NYSE:GMED - Globus Medical Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $89.30
  • Forecasted Upside: 28.23 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$69.64
▲ +0.72 (1.04%)

This chart shows the closing price for GMED by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Globus Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GMED and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GMED

Analyst Price Target is $89.30
▲ +28.23% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Globus Medical in the last 3 months. The average price target is $89.30, with a high forecast of $100.00 and a low forecast of $80.00. The average price target represents a 28.23% upside from the last price of $69.64.

This chart shows the closing price for GMED for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 contributing investment analysts is to buy stock in Globus Medical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/15/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/13/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/12/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/12/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/10/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/8/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/7/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/7/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/5/2021Piper SandlerLower Price TargetNeutral ➝ Neutral$85.00 ➝ $80.00High
10/28/2021Loop CapitalInitiated CoverageBuy$100.00Medium
8/5/2021Morgan StanleyBoost Price TargetEqual Weight$77.00 ➝ $80.00Medium
8/5/2021SVB LeerinkBoost Price TargetOutperform$88.00 ➝ $96.00High
8/5/2021Credit Suisse GroupBoost Price TargetOutperform$86.00 ➝ $91.00High
8/5/2021Wells Fargo & CompanyBoost Price TargetOverweight$78.00 ➝ $90.00High
8/5/2021Canaccord GenuityBoost Price TargetBuy$80.00 ➝ $90.00Medium
8/5/2021Needham & Company LLCBoost Price TargetBuy$82.00 ➝ $92.00Medium
8/5/2021CitigroupBoost Price TargetBuy$81.00 ➝ $93.00Medium
5/5/2021CitigroupBoost Price Target$77.00 ➝ $81.00High
5/5/2021Canaccord GenuityBoost Price TargetBuy$79.00 ➝ $80.00High
5/5/2021BTIG ResearchBoost Price TargetBuy$72.00 ➝ $81.00High
5/5/2021Morgan StanleyBoost Price TargetEqual Weight$72.00 ➝ $77.00High
5/5/2021Wells Fargo & CompanyBoost Price TargetOverweight$71.00 ➝ $78.00High
5/5/2021SVB LeerinkBoost Price TargetOutperform$74.00 ➝ $81.00High
5/5/2021Needham & Company LLCBoost Price TargetBuy$75.00 ➝ $82.00High
2/25/2021Morgan StanleyBoost Price TargetEqual Weight$69.00 ➝ $72.00Medium
2/18/2021CitigroupBoost Price Target$72.00 ➝ $77.00Medium
2/18/2021Needham & Company LLCBoost Price TargetBuy$65.00 ➝ $75.00Medium
2/18/2021BTIG ResearchBoost Price TargetBuy$63.00 ➝ $72.00High
1/29/2021Piper SandlerBoost Price TargetNeutral$55.00 ➝ $63.00High
1/8/2021Credit Suisse GroupBoost Price TargetTop Pick ➝ Outperform$64.00 ➝ $75.00Low
12/15/2020Morgan StanleyBoost Price TargetEqual Weight$58.00 ➝ $69.00Medium
12/8/2020Smith Barney CitigroupInitiated CoverageBuy$72.00Low
10/29/2020Credit Suisse GroupBoost Price TargetOutperform$58.00 ➝ $64.00High
10/19/2020Stifel NicolausInitiated CoverageHold$56.00Medium
8/6/2020OppenheimerInitiated CoverageHold$56.00Medium
8/6/2020Piper SandlerBoost Price TargetNeutral$50.00 ➝ $55.00Low
8/6/2020Wells Fargo & CompanyBoost Price TargetOverweight$54.00 ➝ $56.00Low
8/6/2020Canaccord GenuityBoost Price TargetBuy$56.00 ➝ $60.00High
8/6/2020Credit Suisse GroupBoost Price TargetOutperform$57.00 ➝ $58.00High
8/6/2020Morgan StanleyBoost Price TargetEqual Weight$52.00 ➝ $58.00High
8/6/2020Northland SecuritiesUpgradeMarket Perform ➝ Outperform$65.00High
8/6/2020SVB LeerinkBoost Price TargetOutperform$56.00 ➝ $64.00High
8/6/2020Needham & Company LLCBoost Price TargetBuy$60.00 ➝ $65.00High
7/21/2020Northland SecuritiesInitiated CoverageMarket Perform$50.00Low
7/6/2020Piper SandlerDowngradeOverweight ➝ Neutral$60.00 ➝ $50.00High
5/8/2020UBS GroupLower Price TargetBuy$67.00 ➝ $61.00Medium
5/8/2020Credit Suisse GroupBoost Price TargetOutperform$56.00 ➝ $57.00Low
5/8/2020Morgan StanleyBoost Price TargetEqual Weight$48.00 ➝ $52.00High
5/8/2020SVB LeerinkLower Price TargetOutperform$63.00 ➝ $56.00High
5/8/2020Needham & Company LLCLower Price TargetBuy$63.00 ➝ $60.00High
5/8/2020BTIG ResearchReiterated RatingBuy$53.00High
4/6/2020Wells Fargo & CompanyLower Price TargetOverweight$63.00 ➝ $50.00Low
3/27/2020Morgan StanleyLower Price TargetEqual Weight$60.00 ➝ $48.00Medium
3/18/2020BTIG ResearchUpgradeNeutral ➝ Buy$46.00High
3/6/2020Credit Suisse GroupLower Price TargetOutperform$67.00 ➝ $59.00Medium
2/24/2020Credit Suisse GroupReiterated RatingBuy$67.00High
1/9/2020Cantor FitzgeraldReiterated RatingBuy$64.00High
1/8/2020Credit Suisse GroupBoost Price TargetOutperform$59.00 ➝ $67.00Low
1/7/2020SunTrust BanksInitiated CoverageBuy$67.00Low
1/2/2020Morgan StanleyDowngradeOverweight ➝ Equal WeightHigh
12/18/2019UBS GroupBoost Price TargetBuy$61.00 ➝ $67.00Low
12/17/2019Morgan StanleyBoost Price TargetEqual Weight$57.00 ➝ $60.00Low
12/12/2019Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$63.00Low
11/7/2019BTIG ResearchReiterated RatingHoldLow
11/7/2019Needham & Company LLCReiterated RatingBuy$63.00High
11/7/2019Cantor FitzgeraldBoost Price TargetOverweight$55.00 ➝ $64.00High
10/8/2019Wells Fargo & CompanyBoost Price TargetMarket Perform$42.00 ➝ $53.00High
8/2/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$52.00 ➝ $56.00High
6/5/2019Morgan StanleySet Price TargetHold$45.00Low
5/24/2019Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$50.00 ➝ $41.00Low
5/3/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$57.00 ➝ $52.00High
3/19/2019OppenheimerReiterated RatingHoldLow
3/1/2019Cantor FitzgeraldReiterated RatingBuy$60.00Low
2/28/2019UBS GroupUpgradeNeutral ➝ Buy$55.00High
1/18/2019Cantor FitzgeraldSet Price TargetBuy$60.00Low
1/9/2019Cantor FitzgeraldReiterated RatingBuy$65.00High
1/2/2019Morgan StanleyDowngradeOverweight ➝ Equal Weight$64.00 ➝ $49.00High
12/17/2018Credit Suisse GroupInitiated CoverageOutperform$53.00Medium
11/28/2018UBS GroupInitiated CoverageNeutral$55.00High
11/13/2018Cantor FitzgeraldSet Price TargetBuy$65.00Low
11/9/2018SVB LeerinkBoost Price TargetOutperform$61.00 ➝ $65.00Low
11/9/2018Piper Jaffray CompaniesBoost Price TargetOverweight$62.00Low
11/9/2018OppenheimerSet Price TargetHold$61.00High
9/25/2018Morgan StanleyBoost Price TargetOverweight ➝ Buy$60.00 ➝ $64.00Medium
8/2/2018OppenheimerSet Price TargetHold$57.00Medium
8/2/2018Needham & Company LLCBoost Price TargetBuy$58.00 ➝ $65.00Medium
8/2/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$58.00 ➝ $60.00High
6/27/2018Bank of AmericaDowngradeNeutral ➝ Underperform$55.00High
5/31/2018Cantor FitzgeraldInitiated CoverageOverweight$65.00Low
5/30/2018SVB LeerinkBoost Price TargetOutperform ➝ Outperform$60.00 ➝ $61.00Medium
5/3/2018OppenheimerSet Price TargetHold$52.00Low
5/3/2018Morgan StanleyBoost Price TargetOverweight ➝ Buy$53.00 ➝ $58.00Low
5/3/2018Needham & Company LLCBoost Price TargetBuy ➝ Buy$57.00 ➝ $58.00High
4/16/2018BTIG ResearchReiterated RatingBuy ➝ Neutral$37.00Low
4/4/2018Needham & Company LLCUpgradeHold ➝ Buy$57.00Medium
3/28/2018SVB LeerinkReiterated RatingOutperform ➝ Outperform$56.00 ➝ $60.00Low
3/12/2018Canaccord GenuityReiterated RatingBuy$53.00Low
2/22/2018OppenheimerSet Price TargetHold$49.00Medium
2/22/2018Morgan StanleySet Price TargetOverweight ➝ Buy$48.00 ➝ $53.00Medium
2/22/2018Needham & Company LLCReiterated RatingHoldMedium
2/22/2018Canaccord GenuityReiterated RatingBuy ➝ Positive$47.00 ➝ $53.00Medium
2/22/2018BTIG ResearchBoost Price TargetOutperform ➝ Buy$51.00Medium
1/10/2018BarclaysReiterated RatingSell$36.00Medium
1/10/2018Wells Fargo & CompanyReiterated RatingOutperform$46.00 ➝ $51.00High
1/2/2018BTIG ResearchSet Price TargetBuy$45.00High
1/2/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$48.00High
12/4/2017Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$46.00High
11/20/2017BTIG ResearchSet Price TargetBuy$42.00N/A
11/14/2017GabelliReiterated RatingBuyN/A
11/10/2017Bank of AmericaUpgradeUnderperform ➝ NeutralN/A
11/9/2017Canaccord GenuityReiterated RatingBuy$38.00N/A
11/9/2017BarclaysBoost Price TargetUnderweight$27.00 ➝ $29.00N/A
11/9/2017Needham & Company LLCReiterated RatingHoldN/A
11/9/2017BTIG ResearchReiterated RatingBuy$37.00N/A
10/19/2017Piper Jaffray CompaniesReiterated RatingBuyN/A
10/19/2017BarclaysLower Price TargetUnderweight$28.00 ➝ $27.00N/A
9/26/2017Needham & Company LLCInitiated CoverageHoldHigh
9/22/2017Canaccord GenuityReiterated RatingBuy$38.00Low
9/7/2017BTIG ResearchInitiated CoverageBuy$37.00Low
8/30/2017OppenheimerReiterated RatingHoldHigh
8/18/2017Canaccord GenuityReiterated RatingBuy$37.00Low
8/9/2017BarclaysReiterated RatingUnderweight$30.00 ➝ $28.00Low
8/4/2017GabelliReiterated RatingBuyLow
8/3/2017BarclaysReiterated RatingUnderweight$30.00 ➝ $28.00Low
8/3/2017OppenheimerSet Price TargetHold$35.00High
7/11/2017Morgan StanleyReiterated RatingEqual WeightLow
5/18/2017OppenheimerReiterated RatingHoldLow
5/18/2017Canaccord GenuitySet Price TargetBuy$37.00Low
5/15/2017BarclaysReiterated RatingSell$30.00N/A
5/5/2017BarclaysReiterated RatingSell$30.00Low
5/4/2017OppenheimerSet Price TargetHold$32.00Medium
5/4/2017Canaccord GenuityUpgradeHold ➝ Buy$30.00 ➝ $37.00High
4/24/2017BarclaysDowngradeEqual Weight ➝ Underweight$24.00 ➝ $28.00Low
4/12/2017SVB LeerinkUpgradeMarket Perform ➝ OutperformHigh
3/22/2017OppenheimerReiterated RatingHoldMedium
2/28/2017OppenheimerSet Price TargetHold$29.00N/A
2/28/2017AegisReiterated RatingBuy$31.00N/A
1/23/2017Canaccord GenuityReiterated RatingHold$27.00N/A
1/11/2017Canaccord GenuitySet Price TargetHold$27.00N/A
(Data available from 12/8/2016 forward)

News Sentiment Rating

0.58 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/12/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/11/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2021
  • 8 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/10/2021
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/9/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/9/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
11/8/2021
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/8/2021

Current Sentiment

  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Globus Medical logo
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.
Read More

Today's Range

Now: $69.64
Low: $68.34
High: $69.75

50 Day Range

MA: $73.58
Low: $62.62
High: $79.92

52 Week Range

Now: $69.64
Low: $58.90
High: $84.23

Volume

353,444 shs

Average Volume

457,782 shs

Market Capitalization

$7.03 billion

P/E Ratio

38.48

Dividend Yield

N/A

Beta

1.09

Frequently Asked Questions

What sell-side analysts currently cover shares of Globus Medical?

The following Wall Street research analysts have issued reports on Globus Medical in the last year: BTIG Research, Canaccord Genuity, Citigroup Inc., Credit Suisse Group AG, Loop Capital, Morgan Stanley, Needham & Company LLC, Piper Sandler, Smith Barney Citigroup, SVB Leerink LLC, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for GMED.

What is the current price target for Globus Medical?

10 Wall Street analysts have set twelve-month price targets for Globus Medical in the last year. Their average twelve-month price target is $89.30, suggesting a possible upside of 28.2%. Loop Capital has the highest price target set, predicting GMED will reach $100.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $80.00 for Globus Medical in the next year.
View the latest price targets for GMED.

What is the current consensus analyst rating for Globus Medical?

Globus Medical currently has 2 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GMED will outperform the market and that investors should add to their positions of Globus Medical.
View the latest ratings for GMED.

What other companies compete with Globus Medical?

How do I contact Globus Medical's investor relations team?

Globus Medical's physical mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company's listed phone number is (610) 930-1800 and its investor relations email address is [email protected] The official website for Globus Medical is www.globusmedical.com.